Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Michael O'Riordan

March 25, 2016

News Daily News

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

L.A. McKeown

December 09, 2015

News Industry News

Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA

September 29, 2015

News Conference News ESC 2015

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

L.A. McKeown

August 31, 2015

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Industry News

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

June 05, 2015

News Daily News

研究探索了在氯吡格雷治疗的PCI患者中，糖尿病对血小板反应性的影响

October 10, 2014

News Daily News

Studies Explore Impact of Diabetes on Platelet Reactivity in Clopidogrel-Treated PCI Patients

October 10, 2014

News Daily News

Estudios Exploran el Impacto de la Diabetes sobre la Reactividad Plaquetaria en Pacientes PCI a Tratamiento con Clopodogrel

October 10, 2014

Presentation

Impact of Diabetes and Metabolic Syndrome on Acute and Chronic On-Clopidogrel Platelet Reactivity in Patients with Stable CAD Receiving DES

Presenter: Laurent Feldman

October 06, 2014

News Daily News

El Antidiabético Aleglitazar No Logra Reducir los Resultados Isquémicos de Diabéticos con SCA de Reciente Aparición

L.A. McKeown

April 11, 2014

News Daily News

Diabetes Drug Aleglitazar Fails to Reduce Ischemic Outcomes in Diabetics with Recent ACS

L.A. McKeown

April 11, 2014

News Daily News

DES Outcomes Vary by Diabetes Status, Lesion Complexity

Caitlin E. Cox

March 13, 2014

News Daily News

Los Subgrupos de Alto Riesgo obtienen Protección Renal de la Rosuvastatina

Caitlin E. Cox

October 11, 2013

News Daily News

High-Risk Subgroups Derive Kidney Protection from Rosuvastatin

Caitlin E. Cox

October 11, 2013

News Daily News

Meta-analysis: Early Invasive Strategy Best for Diabetic Patients with NSTE ACS

July 03, 2012

News Daily News

Meta Análisis: La Estrategia Invasiva Precoz es la Mejor en Pacientes Diabéticos con SCASEST

July 03, 2012

News Conference News

RESET: Largest Study to Date of Xience, Cypher Shows Noninferiority

August 31, 2011

Advertisement

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

研究探索了在氯吡格雷治疗的PCI患者中，糖尿病对血小板反应性的影响

Studies Explore Impact of Diabetes on Platelet Reactivity in Clopidogrel-Treated PCI Patients

Estudios Exploran el Impacto de la Diabetes sobre la Reactividad Plaquetaria en Pacientes PCI a Tratamiento con Clopodogrel

Impact of Diabetes and Metabolic Syndrome on Acute and Chronic On-Clopidogrel Platelet Reactivity in Patients with Stable CAD Receiving DES

El Antidiabético Aleglitazar No Logra Reducir los Resultados Isquémicos de Diabéticos con SCA de Reciente Aparición

Diabetes Drug Aleglitazar Fails to Reduce Ischemic Outcomes in Diabetics with Recent ACS

DES Outcomes Vary by Diabetes Status, Lesion Complexity

Los Subgrupos de Alto Riesgo obtienen Protección Renal de la Rosuvastatina

High-Risk Subgroups Derive Kidney Protection from Rosuvastatin

Meta-analysis: Early Invasive Strategy Best for Diabetic Patients with NSTE ACS

Meta Análisis: La Estrategia Invasiva Precoz es la Mejor en Pacientes Diabéticos con SCASEST

RESET: Largest Study to Date of Xience, Cypher Shows Noninferiority

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content